论文部分内容阅读
首批新药Ampyra获批用于改善多发性硬化症患者步行速度日前美国FDA批准Ampyra(dalfampridine)缓释片用于改善多发性硬化症(MS)患者的步行速度。
First batch of new drug Ampyra approved for walking speed in patients with multiple sclerosis The FDA recently approved Ampyra (dalfampridine) sustained-release tablets to improve walking speed in patients with multiple sclerosis (MS).